Avances en el conocimiento de los mecanismos genéticos que favorecen el desarrollo de la leucemia mieloide aguda

T. Boveri, Zur Frage der Entstehung maligner Tumoren, Fischer, Jena, 1914.

Goldman JM, Melo JV. Chronic myeloid leukemia--advances in biology and new approaches to treatment. N Engl J Med. 2003; 349(15):1451-64.

Golomb HM, Tests JR, Vardiman JW. Cytogenetic and ultrastructural features of de novo acute promyelocytic leukemia: The University of Chicago experience (1973-1978). Cancer Genetics and Cytogenetics. 1979; 1:69-78.

Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004;18(2):115-36.

Sanger F, Coulson AR. A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. J Mol Biol. 1975; 94: 441-8.

Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100: 59-66.

Shayegi N , Kramer M , Bornhauser M, et al. The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. Blood. 2013;122: 83-92.

Leisch M, Jansko B, Zaborsky N, Greil R, Pleyer L. Next Generation Sequencing in AML—On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?. Cancers (Basel). 2019;11(2). pii: E252

Ley TJ, Mardis ER, Ding Li, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 2008;456(7218):66-72.

Ilyas AM, Ahmad S, Faheem M1, et al. BMC Genomics. 2015;16(Suppl 1):S5-S12.

Davis JR, Benjamin DJ, Jonas BA. New and emerging therapies for acute

myeloid leukaemia. J Investig Med. 2018;66(8):1088-95.